Billionaire Larry Robbins’ Glenview Capital Management took new positions in semiconductor firm Marvell Technology (NASDAQ:MRVL) and managed care player CVS Health (CVS) in Q4 2023, while exiting its stake in Microsoft (NASDAQ:MSFT) and cutting its position in chip giant Intel (NASDAQ:INTC) by a significant amount.
Glenview Capital disclosed the information in its latest 13F filing for the three months ended December 31, 2023, published on Wednesday.
The hedge fund in Q4 snapped up about 180K shares in Marvell (MRVL) and 746K shares in CVS (CVS). Glenview also picked up new stakes of 1.6M U.S.-listed shares in the world’s largest generic drugmaker Teva Pharmaceutical Industries (TEVA) and 6.07M shares in its smaller rival Viatris (VTRS).
Glenview in Q4 disposed off the ~30K shares it held in Microsoft (MSFT). Additionally, the fund exited its stakes of ~180K shares in medical device maker Medtronic (MDT), 218K shares in Tinder-parent Match Group (MTCH), and 433K shares in chemicals company Dupont (DD).
The hedge fund trimmed its position in Intel (INTC) to 344K shares in Q4 from 2.09M in Q3, a 83.5% decrease. Glenview cut its stake in Amazon (AMZN) to 694K shares from 954K, in ride-hailing firm Uber (UBER) to 1.96M shares from 2.11M shares, and in travel agency Expedia (EXPE) to 701K shares from 807K shares.
Among other moves, Glenview raised its stake in Facebook-owner Meta Platforms (META) to 157K class A shares in Q4 from 55K in Q3.
According to Forbes, Larry Robbins’ real time net worth is $1.9B.
More on 13F filings
Glenview Capital takes in Marvell, cuts stake in Intel and exits Microsoft (NASDAQ:MRVL)
